Jeligo

Linagliptin, the active ingredient in Jeligo, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Jeligo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory documentation to support global distribution through established logistics networks.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycaemic control as an adjunct to diet and exercise. Combination therapy with metformin: provides additional HbA1c reduction when used together. Renal impairment: can be used without dose adjustment, offering a convenient option for patients with reduced kidney function.

Adverse reactions may occur with linagliptin therapy.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Upper respiratory tract infection: symptoms resembling a cold. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas that may present with severe abdominal pain. - Severe hypersensitivity reactions: including rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or hepatitis.

Linagliptin should be used with appropriate clinical caution.

Renal function monitoring: assess kidney status before initiation and periodically thereafter. Hepatic function monitoring: evaluate liver enzymes at baseline and during therapy. Not for type 1 diabetes or diabetic ketoacidosis: the drug is ineffective in these conditions. Pregnancy and lactation: safety not established; use only if benefits outweigh risks. Elderly patients: monitor for hypoglycaemia when combined with insulin or sulfonylureas. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Linagliptin may interact with other medicines; some require avoidance, others close monitoring.

Major Interactions (Avoid): - Duplicate DPP‑4 inhibition: concurrent use of another DPP‑4 inhibitor. - Strong CYP3A4 inducers (e.g., rifampicin): may markedly reduce linagliptin exposure.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycaemia, monitor glucose levels. - Thiazide diuretics: may affect blood glucose control. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential impact on renal function, especially in susceptible patients.